Ind-Swift Laboratories Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Ind-Swift Laboratories Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹356

Market cap₹3.1K Cr

P/E47.6

Published7 Sept 2026

What the Q1 FY27 call signalled

2 of 3 strong

RevenueRank 2

MarginRank 3

CapexYes

Not discussed on this call: fundraise, order book.

The short version

Expecting over 50% growth this year (FY27), targeting around ₹900 crore in revenue this year (Page 13). Revenue growth target: ₹1,200 crore by FY29 with 20-25% CAGR expected medium-term continuation beyond FY27.

From Ind-Swift Laboratories Ltd's Q1 FY27 earnings-call transcript · updated 7 Sept 2026.

Revenue & Sales Performance

Rank 2

Expecting over 50% growth this year (FY27), targeting around ₹900 crore in revenue this year (Page 13).
Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14).
CDMO partnerships with Viatris, Manx, Arrotex expected to contribute incremental revenue of ₹200-220 crore in FY27, scaling contract manufacturing (Page 3, 5, 14).
Own-brand export sales growing strongly; export business expected to be ~45% CDMO by FY27 with ₹750 crore in export sales total (Page 6).
New molecule launches expected in FY27-FY29 (e.g., Clarithromycin, Esomeprazole, Macrogol sachets) to strengthen portfolio and drive growth (Page 4, 7, 14).
Revenue guidance of ₹1200 crore by FY29, potentially conservative and may be revised upwards after FY27 results (Page 8, 13).
Targeting sustainable EBITDA margins above 18%, aiming for 20%-22% in upcoming quarters (Page 7, 13).
Filed dossiers to increase from 2100 to 2500 by Q4 FY27, supporting long-term growth (Page 11).

Profitability & Margins

Revenue growth target: ₹1,200 crore by FY29 with 20-25% CAGR expected medium-term continuation beyond FY27.
EBITDA margin expected to surpass 18% post Q2 FY27, potentially rising to 21-22%.
PAT and operating profit margins showing strong improvement; Q1 FY27 PAT margin improved to 13.26% from 4.99% YoY.
Incremental CDMO revenue expected around ₹150 crore this year; export sales forecast at ₹750 crore with ~45% from CDMO.
Own-brand products driving margin expansion; export business shifting favorably towards high-margin own brands.
Capacity expansions and new molecule launches set to support accelerated growth and profitable scale-up.
FY30 vision targets ₹1,500 crore revenue and ₹200+ crore net profit with sustainable margins.
Conservative revenue guidance with potential for earlier achievement depending on capacity expansion success.

See what Ind-Swift Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

Ind-Swift Laboratories plans a capex of approx. ₹250 crores over the next 2 to 2.5 years.
Capex will be allocated towards:
- Setting up a new warehouse near the factory premises.
- Capacity enhancement of existing production facilities.
- Developing the Jammu division with PIC/S and EU compliance.
Additional capex of ₹50 to 75 crores is expected if new CDMO partnerships materialize, potentially generating ₹150+ crores in revenue.
The company intends to utilize ₹250 crores cash on the books gradually over 2.5 years for these investments.
There are discussions underway for domestic brand acquisitions and inorganic growth through partnerships with existing overseas customers.
No immediate plan to divest the 7.8% stake in Synthimed; holding for strategic partnership though future monetization is possible.
R&D investments include setting up a new facility and working on regulatory filings and new molecule development for FY27-29.

Fundraising & Capital Structure

No direct mention of any current or planned new fundraising through debt or equity in the call transcript.
The company has already cleared its previous high debt levels through sale of API business and is currently cash rich (approx. ₹250 crore on books).
Planned capex of ₹250 crore over 2.5 years to be funded gradually using existing cash and internal accruals.
No indications from management about any immediate need or plan for raising new debt or equity.
Focus appears to be on organic growth, capacity expansion, and selective acquisitions using internal resources.

See what Ind-Swift Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The company is actively engaged with two customers for signing deals on existing CDMO products.
Capex of ₹250 crores is planned over ~2.5 years to support these expansions.
No specific order book value is disclosed yet; agreements are pending signature.
The company anticipates incremental revenue of approx. ₹150 crores from new CDMO clients linked to ₹50-75 crores capex.
Discussions with existing and potential customers ongoing; names will be disclosed post agreement.
The Viatris partnership began contributing ₹5-6 crores in Q1 FY27 with expected growth to ₹100-130 crores over two years.
Additional product filings and launches planned to boost order inflows.
Capacity utilization has headroom (~70%), supporting order scaling without immediate capacity constraints.

How does Ind-Swift Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisInd-Swift Laboratories Ltd

Rev 2Mar 3

See where Ind-Swift Laboratories Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

Ind-Swift Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹151 Cr, net profit ₹10 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Ind-Swift Laboratories Ltd Q1 FY27 results?

What is Ind-Swift Laboratories Ltd share price analysis?

Ind-Swift Laboratories Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 47.6 with a market cap of ₹3,095 Cr. Investors should review the full earnings analysis for detailed insights.

Is Ind-Swift Laboratories Ltd planning capital expenditure?

Ind-Swift Laboratories plans a capex of approx.

Keep Ind-Swift Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.